SCHEMBL6948557

SCHEMBL6948557

CCc1nc(N2CCc3ccccc3CC2)c([N+](=O)[O-])c(=O)n1CC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
ALDH1A1 P00352 4/20 0.42
HTT P42858 3/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MITF O75030 1/20 0.42
AGTR1 P30556 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TLR9 Q9NR96 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GPR55 Q9Y2T6 1/20 0.38
POLB P06746 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946348 0.88 MAPT (0.42) MAPTALDH1A1HTTLMNANPC1
SCHEMBL6954007 0.85 MAPT (0.40) MAPTALDH1A1HTTLMNANPC1
SCHEMBL6952584 0.82 CYP2C9 (0.40) MAPTALDH1A1HTTLMNANPC1
SCHEMBL6952822 0.80 CYP2C9 (0.39) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL6952859 0.79 CYP2C9 (0.40) MAPTALDH1A1HTTLMNANPC1
SCHEMBL6952446 0.79 CYP2C9 (0.38) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL6953752 0.79 CYP2C9 (0.40) MAPTALDH1A1HTTLMNARAB9A
SCHEMBL6947618 0.78 CYP2C9 (0.37) MAPTHTTLMNANPC1RAB9A
SCHEMBL6952315 0.77 MAPT (0.42) MAPTALDH1A1HTTLMNANPC1
SCHEMBL6950082 0.77 ALDH1A1 (0.39) MAPTALDH1A1HTTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed